General Medicine: Open Access

ISSN - 2327-5146

Non-glucose-dependent anti-atherosclerotic effects of pioglitazone: An overlooked phenomenon

Joint Webinar: 37th European Cardiology Conference & 33rd International Congress on Prevention of Diabetes and Complications & 5th World Congress on Psychiatry & Psychological Syndromes

October 31, 2022 | Webinar

Nanwei Tong*, Qingxing Xie, Jinfang Ma and Xiaohui Pan

West China Hospital of Sichuan University, China

Posters & Accepted Abstracts: Gen Med (Los Angeles)

Abstract :

Pioglitazone is a classic insulin sensitizer that has its pharmacological effects principally by activating Peroxisome Proliferator-Activated Receptor γ (PPAR-γ). Not only is PPAR-γ involved in the glucose metabolism, but also it is related to Atherosclerosis (AS). Several large prospective randomized controlled clinical trials have intervened diverse crowds (patients with type 2 diabetes and different AS risks, or nondiabetic patients with stroke and insulin resistance, representing primary and secondary prevention of AS respectively) with pioglitazone, and the occurrences of AS-related macrovascular events were observed in them. The results of those trials including the PROactive, IRIS and TOSCA.IT study have been analyzed to evaluate the anti-AS effect of pioglitazone in diverse populations (primary and secondary prevention of AS), and compared with the evidence for the macrovascular protective effects of metformin. The conclusions are that pioglitazone can reduce macrovascular events in AS primary and secondary prevention population, whose evidence is superior to metformin, and at least part of the anti-AS effect of pioglitazone is glucose-independent. Furthermore, we summarize the proposed mechanisms.

Top